Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 5/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.44 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14438801 | 1.00 | EPHX2 (0.53) | EPHX2SMN1; SMN2KDM4EFAAHCNR1 | |
| SCHEMBL13165219 | 1.00 | EPHX2 (0.53) | EPHX2SMN1; SMN2KDM4EFAAHCNR1 | |
| SCHEMBL14118063 | 0.97 | EPHX2 (0.50) | EPHX2SMN1; SMN2KDM4EFAAHCNR1 | |
| SCHEMBL12673829 | 0.97 | EPHX2 (0.50) | EPHX2SMN1; SMN2KDM4EFAAHCNR1 | |
| SCHEMBL15507477 | 0.97 | EPHX2 (0.50) | EPHX2SMN1; SMN2KDM4EFAAHCNR1 | |
| SCHEMBL13147054 | 0.97 | EPHX2 (0.50) | EPHX2SMN1; SMN2KDM4EFAAHCNR1 | |
| SCHEMBL15357541 | 0.97 | EPHX2 (0.50) | EPHX2SMN1; SMN2KDM4EFAAHCNR1 | |
| SCHEMBL19752250 | 0.94 | EPHX2 (0.51) | EPHX2SMN1; SMN2KDM4EADRA1A | |
| SCHEMBL29763934 | 0.94 | EPHX2 (0.48) | EPHX2SMN1; SMN2KDM4EFAAHCNR1 | |
| SCHEMBL12666086 | 0.92 | SMN1; SMN2 (0.61) | EPHX2SMN1; SMN2KDM4EFAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2932981-B1 | Albumin-binding derivatives of GLP-1 | NOVO NORDISK AS (DK) | 2021-06-16 | — | — | EP | disclosed |
| US-8895694-B2 | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use | NOVO NORDISK A/S (DK) | 2014-11-25 | — | — | US | disclosed |
| US-20130244931-A1 | Novel GLP-1 Derivatives | NOVO NORDISK AS (DK) | 2013-09-19 | — | — | US | disclosed |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2011-04-07 | — | — | US | disclosed |
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | NOVO NORDISK A/S (DK) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082079-A1 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLP1R, GIPR, GCGR | EPHX2 4344/4885SMN1; SMN2 3448/4885KDM4E 3010/4885 |
| US-20130244931-A1 | Novel GLP-1 Derivatives | GLP1R, GIPR, IAPP | EPHX2 4797/4885SMN1; SMN2 3474/4885KDM4E 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.